World Health Organization site
Skip Navigation Links

Please fill this short user satisfaction survey


Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: EUCTR
Last refreshed on: 16 January 2017
Main ID:  EUCTR2012-002639-27-BG
Date of registration: 13/03/2013
Prospective Registration: Yes
Primary sponsor: Mitsubishi Tanabe Pharma Corporation (MTPC)
Public title: A study to assess long-term safety and effectiveness of MT-1303 in subjects who completed the MT-1303-E04 study.
Scientific title: A phase II, multicentre study to evaluate the long-term safety and efficacy of MT-1303 in subjects with relapsing-remitting multiple sclerosis who have completed the MT-1303-E04 study
Date of first enrolment: 30/04/2013
Target sample size: 400
Recruitment status: Not Recruiting
URL:  https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-002639-27
Study type:  Interventional clinical trial of medicinal product
Study design:  Controlled: no Randomised: yes Open: Single blind: no Double blind: Parallel group: Cross over: no Other: yes Other trial design description: This study is a parallel group 2 part study. Part 1 is double-blind; Part 2 is open-label If controlled, specify comparator, Other Medicinial Product: no Placebo: no Other: no Number of treatment arms in the trial: 3  
Phase:  Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): yes Therapeutic confirmatory - (Phase III): no Therapeutic use (Phase IV): no
Countries of recruitment
Belgium Bosnia and Herzegovina Bulgaria Canada Croatia Czech Republic Finland Germany
Hungary Italy Latvia Lithuania Poland Russian Federation Serbia Spain
Sweden Switzerland Turkey Ukraine United Kingdom
Contacts
Name: Clinical Project Manager   
Address:  Dashwood House, 69 Old Broad Street EC2M 1QS London United Kingdom
Telephone: 00442070655000
Email: KGreenough@m-pharma.co.uk
Affiliation:  Mitsubishi Pharma Europe Ltd (MPE)
Name: Clinical Project Manager   
Address:  Dashwood House, 69 Old Broad Street EC2M 1QS London United Kingdom
Telephone: 00442070655000
Email: KGreenough@m-pharma.co.uk
Affiliation:  Mitsubishi Pharma Europe Ltd (MPE)
Key inclusion & exclusion criteria
Inclusion criteria:
Completion of the 24-week Treatment Period in MT-1303-E04 as per protocol
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 400
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion criteria:
1. Permanent discontinuation of study medication prior to the End of Treatment (EOT) Visit in MT-1303-E04
2. Newly diagnosed diabetes mellitus during MT-1303-E04


Age minimum:
Age maximum:
Gender:
Female: yes
Male: yes
Health Condition(s) or Problem(s) studied
Relapsing-remitting multiple sclerosis (RRMS)
MedDRA version: 18.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders
Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Intervention(s)

Product Name: MT-1303
Product Code: MT-1303
Pharmaceutical Form: Capsule
INN or Proposed INN: MT-1303
Current Sponsor code: MT-1303
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 0.1-

Product Name: MT-1303
Product Code: MT-1303
Pharmaceutical Form: Capsule
INN or Proposed INN: MT-1303
Current Sponsor code: MT-1303
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 0.2-

Product Name: MT-1303
Product Code: MT-1303
Pharmaceutical Form: Capsule
INN or Proposed INN: MT-1303
Current Sponsor code: MT-1303
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 0.4-

Primary Outcome(s)
Timepoint(s) of evaluation of this end point: Various timepoints throughout the study - please refer to the detailed Time and Events Schedule in the protocol for full details
Secondary Objective: • To evaluate the long-term effects of MT-1303 on magnetic resonance imaging (MRI) parameters, clinical outcomes and health-related quality of life in subjects with RRMS
• To evaluate the pharmacodynamics of MT-1303 in subjects with RRMS
Primary end point(s): Safety Assessments
• Adverse events (AEs)
• Vital signs
• 12-lead electrocardiogram (ECG)
• 3-lead Holter ECG monitoring
• Routine safety laboratory assessments
• Physical examination
• Optical coherence tomography (OCT)
Main Objective: To evaluate the long-term safety and tolerability of MT-1303 in subjects with RRMS
Secondary Outcome(s)
Secondary end point(s): Clinical Efficacy Endpoints:
• Annualised Relapse Rate (ARR)
• Time to first confirmed relapse
• Proportion of subjects who remain relapse-free at End of Treatment (EOT)
• Change from baseline in total Expanded Disability Status Scale (EDSS) score at EOT
• Change from baseline in total Multiple Sclerosis Functional Composite (MSFC) score at EOT

MRI Endpoints:
• Number of MRI Gd-enhanced T1-weighted lesions
• Number and volume of new or enlarged T2-weighted lesions
• Change and percent change in brain volume at EOT
• Magnetisation Transfer Ratio (MTR) related endpoints will be explored. Details to be specified in the Statistical Analysis Plan (SAP) (selected centres only)

Pharmacodynamic Endpoints:
• Lymphocyte counts
• Lymphocyte subsets (selected centres only)

Subject-reported Endpoints:
• Change from baseline in MSQOL-54 at EOT.
Timepoint(s) of evaluation of this end point: Various timepoints throughout the study - please refer to the detailed Time and Events Schedule in the protocol for full details
Secondary ID(s)
MT-1303-E05
2012-002639-27-GB
Source(s) of Monetary Support
Mitsubishi Tanabe Pharma Corporation (MTPC)
Secondary Sponsor(s)
Ethics review
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history Please fill this short user satisfaction survey